2026-04-05T12:51:33Zhttps://recercat.cat/oai/request
oai:recercat.cat:2445/1782312025-12-05T12:27:28Zcom_2072_1057col_2072_478916col_2072_478917
RECERCAT author Ljungman, Per author Camara, Rafael de la author Mikulska, Malgorzata author Tridello, Gloria author Aguado, Beatriz author Zahrani, Mohsen Al author Apperley, Jane author Berceanu, Ana author Martino Bofarull, Rodrigo author Calbacho, María author Ciceri, Fabio author López Corral, Lucía author Crippa, Claudia author Fox, Maria Laura author Grassi, Anna author Jimenez, Maria Jose author Demir, Safiye Koçulu author Kwon, Mi author Llamas, Carlos Vallejo author López Lorenzo, José Luis author Mielke, Stephan author Orchard, Kim author Parody, Rocío author Vallisa, Daniele author Xhaard, Alienor author Knelange, Nina Simone author Cedillo, Angel author Kröger, Nicolaus author Piñana, José Luis author Styczynski, Jan 2021-06-10T16:01:04Z2021-06-10T16:01:04Z2021-06-022021-06-10T15:26:10Z This study reports on 382 COVID-19 patients having undergone allogeneic (n = 236) or autologous (n = 146) hematopoietic cell transplantation (HCT) reported to the European Society for Blood and Marrow Transplantation (EBMT) or to the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH). The median age was 54.1 years (1.0-80.3) for allogeneic, and 60.6 years (7.7-81.6) for autologous HCT patients. The median time from HCT to COVID-19 was 15.8 months (0.2-292.7) in allogeneic and 24.6 months (-0.9 to 350.3) in autologous recipients. 83.5% developed lower respiratory tract disease and 22.5% were admitted to an ICU. Overall survival at 6 weeks from diagnosis was 77.9% and 72.1% in allogeneic and autologous recipients, respectively. Children had a survival of 93.4%. In multivariate analysis, older age (p = 0.02), need for ICU (p < 0.0001) and moderate/high immunodeficiency index (p = 0.04) increased the risk while better performance status (p = 0.001) decreased the risk for mortality. Other factors such as underlying diagnosis, time from HCT, GVHD, or ongoing immunosuppression did not significantly impact overall survival. We conclude that HCT patients are at high risk of developing LRTD, require admission to ICU, and have increased mortality in COVID-19. cc by (c) Ljungman et al., 2021 http://creativecommons.org/licenses/by/3.0/es/ info:eu-repo/semantics/openAccess COVID-19 Mortalitat Cèl·lules mare COVID-19 Mortality Stem cells COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion